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ABSTRACT
Adenosine deaminases acting on RNA (ADARs) are
involved in RNA editing that converts adenosines
to inosines in double-stranded RNAs. ADAR1 was
demonstrated to be functional on different viruses
exerting either antiviral or proviral effects. Concern-
ing HIV-1, several studies showed that ADAR1 fa-
vors viral replication. The aim of this study was to
investigate the composition of the ADAR1 ribonu-
cleoprotein complex during HIV-1 expression. By
using a dual-tag affinity purification procedure in
cells expressing HIV-1 followed by mass spectrome-
try analysis, we identified 14 non-ribosomal ADAR1-
interacting proteins, most of which are novel. A sig-
nificant fraction of these proteins were previously
demonstrated to be associated to the Long INter-
spersed Element 1 (LINE1 or L1) ribonucleoparticles
and to regulate the life cycle of L1 retrotransposons
that continuously re-enter host-genome.
Hence, we investigated the function of ADAR1 in
the regulation of L1 activity.
By using different cell-culture based retrotranspo-
sition assays in HeLa cells, we demonstrated a novel
function of ADAR1 as suppressor of L1 retrotranspo-
sition. Apparently, this inhibitory mechanism does
not occur through ADAR1 editing activity. Further-
more, we showed that ADAR1 binds the basal L1
RNP complex. Overall, these data support the role
of ADAR1 as regulator of L1 life cycle.
INTRODUCTION
Adenosine deaminases that act on RNA (ADARs) catalyze
the conversion of adenosine (A) to inosine (I) in double-
stranded RNA (dsRNA) substrates (1). Three ADAR en-
zymes are present in mammals (ADAR1-3). ADAR1 and
ADAR2 are expressed in most tissues and appear catalyti-
cally active (2), whereas ADAR3 is expressed only in brain
and its catalytic activity has not been yet demonstrated
(2). Two ADAR1 isoforms are known: the full-length p150
ADAR1 form whose expression is induced by interferon
and localizes in both nucleus and cytoplasm, and the short
p110 ADAR1 form that is constitutively expressed and
found predominantly in the nucleus (3).
ADAR1 p150 and p110 isoforms are both active deami-
nases, with the catalytic domain at the C-terminal and three
double-stranded RNA binding motifs in the central region
(dsRBD). One Z-DNA binding motif is present at the N-
terminal in p110 ADAR1 and two motifs in p150 ADAR1
(Z! in p110; Z" and Z! in p150) (1). Since I is interpreted
as guanosine (G) by the cellular machinery, RNA editing
within the coding sequence of a mRNA can result in codon
changes that may lead to the formation of an altered protein
(2,4). Nonetheless, it has been recently demonstrated that
most A-to-I RNA editing events occur within non-coding
regions, most particularly in Alu elements, affecting differ-
ent aspects of the RNA metabolism (2,4).
Furthermore, growing evidence supports a role of
ADAR1 in the replication process of different viruses (5).
Depending on the type of virus, ADAR1 can either act
as antiviral or proviral factor (5). In particular, ADAR1 fa-
vors replication of vesicular stomatitis virus (6,7), hepatitis
D virus (8), dengue virus (9), human T-cell leukemia virus
type 1 and type 2 (10) and many other viruses (5). ADAR1
exerts an antiviral effect on viruses, such as lymphocytic
choriomeningitis virus (11), bovine viral diarrhea virus (12)
and hepatitis C virus (13). For some viruses, such as In-
fluenza A Virus (9,14,15), there are some discrepancies in
the results obtained so far and therefore additional studies
are required to completely understand the role of ADAR1
in their life cycle.
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Concerning lentiviruses, most of the published data sup-
port the hypothesis that ADAR1 exerts a positive effect on
Human Immunodeficiency type 1 Virus or HIV-1 (16–19)
and Equine Infectious Anemia Virus replication (20). In
particular, over-expressed ADAR1 increases the accumula-
tion of HIV-1 proteins with a mechanism that is editing-
independent (17–19). Moreover, virions produced in the
presence of over-expressed ADAR1 are released more effi-
ciently and display enhanced infectivity (17). Furthermore,
it was clearly demonstrated that ADAR1 binds and edits
viral transcripts in different regions, such as the 5′ untrans-
lated region, within the Tat and Rev coding sequences and
in the vicinity of Rev responsive element within the Env
transcript (16,17). Finally, silencing of ADAR1 expression
in Jurkat T cells causes an impairment of HIV-1 replication
(19).
Long interspersed elements 1 (LINE1 or L1) are the
most abundant autonomous retrotransposon, accounting
for ∼ 17% of human DNA. L1 elements have the potential
of shaping the human genome by their own retrotranspo-
sition, using a ‘copy and paste’ process through an RNA
intermediate to relocate in genomic DNA, and bymobiliza-
tion of non-autonomous elements (Alu, SVA and processed
pseudogenes) (21). The full-length L1 transcript is ∼ 6 kb
long and contains a 5′ untranslated region (5′UTR), two
non-overlapping open reading frames (ORF1 and ORF2)
that are essential for L1mobilization and a 3′ UTR.ORF1p
is a 40 kDa RNA binding protein with nucleic acid chap-
erone activity (22), whereas ORF2p is a 150 kDa protein
that contains both endonuclease and reverse transcriptase
activities (21,23,24). Recently, a thirdORF,ORF0, has been
found in the 5′ UTR sequence, expressed from an anti-
sense promoter (25) and with a still unknown function. It
seems that ORF0 marginally influences the retrotransposi-
tion process (25). The 3′UTR contains a weak polyadenyla-
tion signal. The LINE1 RNA ends with a poly(A) tail that
is critical for an efficient retrotransposition process (26).
Although most of the L1 copies are functionally inactive
due to 5′ truncation, internal deletions and other mutations
(27), about 80–100 copies are still retrotransposition com-
petent in the human genome (27,28). L1 requires host fac-
tors in order to complete its life cycle (29). At the same time,
most of the L1 insertions are detrimental to the host, there-
fore several mechanisms have evolved to restrict the retro-
transposition events (21).
The aim of the work described here was to examine
the composition of the ADAR1 ribonucleoprotein (RNP)
proteome during HIV-1 expression. To this end, ADAR1-
binding proteins were isolated using a dual-tag affinity pu-
rification system in HIV-1-expressing cells and identified by
mass spectrometry. Fourteen non-ribosomal proteins were
identified using this strategy and strikingly we found that a
good fraction of them were previously reported as associ-
ated with the L1–RNP complexes (30–32). Moreover, some
of these proteins were also shown to regulate the L1 life cy-
cle.We therefore sought to investigate whether ADAR1was
able to affect L1 retrotransposition and found that this en-
zyme may act as restriction factor by limiting L1 mobility.
Overall our results underpin the role of ADAR1 in regulat-
ing both exogenous viruses and endogenous parasites and
pave the way toward a better comprehension of the mecha-
nisms that lead to the control of the retrotransposon activ-
ity.
MATERIALS AND METHODS
Cells and transfection
293T cells and HeLa cells were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM). The complete medium was
supplementedwith 10% fetal calf serum, 50U/ml penicillin,
50 #g/ml of streptomycin and 2mML-glutamine. Depend-
ing on the assay, cells were transfected by using transit-LT1
(Mirus) or lipofectamine2000 (Invitrogen) reagents accord-
ing to the protocol provided by the manufacturer.
Plasmids
pADAR1-p150-V5 (expressing the full-length p150
ADAR1 wt enzyme fused with a C-terminal V5/6xHis
double tag) and pADAR1-Dcat (expressing an ADAR1
p150 mutant that lacks the deaminase domain and fused
with a C-terminal V5/6xHis double tag) and pV5 vector
(pcDNA3.1/V5 empty vector) were previously described
(18). HIV-1 proviral DNA (pNL4-3) was obtained through
the NIH AIDS Reagent Program. Retrotransposition
cassettes pJM101/L1.3 (containing an active human L1
[L1.3] equipped with a mneoI retrotransposition indicator
cassette) and pJM105/L1.3 (identical to pJM101/L1.3
but containing a missense mutation in the RT domain of
the ORF2 gene) and pES2TE1 (similar to pJM101/L1.3,
containing a T7 gene10 epitope tag on the C-terminus
of ORF1p and a FLAG-HA tag on the C-terminus of
ORF2p) were previously described elsewhere (33–35).
Retrotransposition cassettes pYX014 (containing an active
human L1RP equipped with a Fluc retrotransposition
indicator cassette) and pYX015 (containing a missense
mutation in the ORF1 sequence) were previously described
(36). The pc-L1-FH is an expression construct of L1RP
containing an ORF1 fused to a HA-FLAG double tag,
as previously described (30). Three anti-ADAR1 unique
29mer shRNA constructs and a scrambled non-effective
shRNA cassette (scr shRNA) cloned in retroviral GFP
vector (pGFP-V-RS plasmid) pre-designed and tested and
the empty vector pGFP-V-RS plasmid were purchased
from OriGene. The sequences of the shRNAs directed
against ADAR1 are the following:
shRNA5:CCTGTGGAATCCAGTGACATTGTGCC
TAC; shRNA6:AAGACAGCAACTCCACATCTGCCT
TGGAA; shRNA7:AGACTCCGTACCATGTCCTGTA
GTGACAA;
Antibodies
The following antibodies or beads were employed in
this study: Anti-V5-tag magnetic beads (MBL), NiNTA
beads (Qiagen), anti-V5 (Invitrogen), anti-ADAR1
(Santa Cruz Biotechnology), anti-SFPQ/PSF (abcam),
anti-NONO/p54nrb (Bethyl), anti-hnRNP L (abcam),
anti-NCL (Santa Cruz Biotechnology), anti-PABP (Santa
Cruz Biotechnology), anti-HSP70 (Santa Cruz Biotech-
nology), anti-GAPDH (Millipore), anti-FLAG M2
(Sigma-Aldrich), anti-T7 epitope tag (Millipore), anti-
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phospho-eIF-2" (Ser51) and anti- eIF-2" (Cell Signaling)
and control IgG (Santa Cruz Biotechnology).
L1 retrotransposition assay
For the Fluc assay, HeLa cells were seeded in 24-well plates
and grow up to 60% confluence and then transfected in
triplicate with 250 ng of the different anti-ADAR1 shRNA
plasmids (shRNA5-7) or the relative controls (empty vec-
tor and scr shRNA). Forty-eight hours later cells were fur-
ther transfected with the pYX014 plasmid. Twenty-four
hours post-transfection puromycin (2.5 #g/ml) was added
to culture medium. Four days after pYX014 transfection,
cells were lysed for luminescence analysis using the Dual-
Luciferase Reporter Assay System (Promega) following the
manufacturer’s instruction. L1 activity was measured as
the Fluc/Rluc ratio as previously reported (36). To con-
firm that the Fluc signals result from retrotransposition, we
used the pYX015 cassette (that carries a missense mutation
that dramatically impairs retrotransposition) in place of the
pYX014 following the same experimental procedure.
For the G418-resistance-based retrotransposition assay,
HeLa cells were seeded into 24-well plates and the day
after transfected in triplicate with 250 ng of the differ-
ent anti-ADAR1 shRNA plasmids or the relative controls
(empty vector and scr shRNA). Twenty-four hours post-
transfection, puromycin (2.5#g/ml) was added in complete
medium. Twenty-four hours later, cells were trypsinized, re-
suspended in DMEMmedium and seeded in 12-well plates.
The day after, cells were further transfected with 500 ng of
pJM101/L1.3 cassette and 72 h later cells were trypsinized,
resuspended in DMEM medium and seeded in T25 flasks.
One day later, transfected cells were supplemented with
DMEM with G418 (800 #g/ml). After 10–12 days of con-
tinued G418 selection, the remaining cells were fixed with
0.4% paraformaldehyde, stained with 0.1% crystal violet so-
lution and the foci number counted. Within each experi-
ment results were normalized for transfection efficiency. In
particular, HeLa cells were first transfectedwith the shRNA
plasmids as described above and after 48 h were further
transfected with pJM101/L1.3 and pDsRed-Express plas-
mid (Clontech) followed by FACS analysis after 72 h.
In each retrotransposition experiment, some wells of
transfected HeLa cells were lysed and used for Western blot
(WB) analysis to monitor the down-regulation of ADAR1
throughout the experiment. Furthermore, to confirm the
specificity of the results obtained, the pJM105/L1.3 cassette
(identical to pJM101/L1.3 but containing a point mutation
that dramatically impairs retrotransposition) or pcDNA3.1
plasmid were transfected in place of the pJM101/L1.3 fol-
lowing the same experimental procedure.
For experiments addressing the effect of ADAR1-V5
over-expression on L1 retrotransposition, HeLa cells were
transiently co-transfected with 250 ng of pYX014 cassette
and different amounts of pADAR1-p150-V5 (ranging from
1:1 to 25:1 ratio between the two plasmids) or pV5 empty
vector. Twenty-four hours post-transfection, puromycin
(2.5 #g/ml) was added and four days after pYX014 trans-
fection, cells were lysed for luminescence analysis using the
Dual-Luciferase Reporter Assay System (Promega) follow-
ing the manufacturer’s instruction. L1 activity was mea-
sured as the Fluc/Rluc ratio as previously reported (36).
Dual tag affinity purification
293T cells were plated in 100 mm dishes. The following day
cells were co-transfected with 8 #g of HIV-1 proviral DNA
(pNL4-3) together with 12 #g of either pADAR1-p150-V5
or pV5 vector.
Transfected 293T cells were lysed in NP40 buffer (0.5%
NP40, 50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20,
50 mM NaH2PO4, pH 8, cocktails of protease and phos-
phates inhibitors from Roche and Sigma-Aldrich, respec-
tively) supplemented with 10 mM imidazole for 30 min on
ice. A total of 30 mg of cell extracts were incubated with 120
#l of the NiNTA Magnetic Beads (Qiagen) for 3 h at 4◦C
followed by several washes (using NP40 buffer with 20 mM
imidazole) and elution of His-tagged native protein com-
plex from the beads (using NP40 buffer with 250 mM imi-
dazole). The eluted protein complex was then subjected to a
second step of immunoprecipitation (IP) using 200#l of the
anti-V5-tag MBL for 2 h at 4◦C followed by several washes
with NP40 buffer. The resulting bead-associated complexes
were resuspended in SDS loading buffer and stored at –
80◦C.
RESULTS
Nano-LC MS analysis of ADAR1-binding proteins
In order to characterize ADAR1-binding partners in HIV-1
expressing cells, we employed a dual tag affinity purification
procedure that allows identification of target-associated na-
tive protein complexes with low background. To this aim,
we co-transfected 293T cells with HIV-1 proviral DNA
(pNL4-3), together with either pADAR1-p150-V5 or pV5
empty vector. Forty-eight hours post-transfection, total cell
extract was prepared and 30 mg subjected to dual-tag affin-
ity procedure.
Sypro Ruby-stained electrophoretic gels of the immuno-
complex recovered showed relatively few bands in pV5
empty vector lane compared with those in pADAR1-p150-
V5 (Figure 1); therefore, proteins were in-gel digested and
analyzed by mass spectrometry (nano-LCMS) as described
in the Supplementary Materials and Methods.
Table 1 lists 22 proteins identified as putative ADAR1-
binding factors. Fourteen putative ADAR1-binding pro-
teins are either components of cytoskeleton (TUBB4B and
TUBB) or heat-shock proteins (HSPA1L,HSPA1A/1B and
HSPA8) or DNA/RNA binding proteins (TOP1, ADAR2,
PSF, DHX15, NCL, PABPC1, NONO and hnRNP L)
most of which are involved in different aspects of RNA
metabolism or belong to the Stress Granules (SG) com-
plex (G3BP2, PABPC1). Seven ribosomal proteins were
also identified along with URB1, i.e. the URB1 ribosome
biogenesis 1 homolog ofS. cerevisiae involved in 60S riboso-
mal subunit biogenesis (37), which are likely contaminants
of the affinity purification procedure and therefore were
excluded from further analysis (38,39). As expected, some
of the proteins indentified, such as ADAR2 and NONO,
were previously reported to interact with ADAR1 (40–42),
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Figure 1. Results of the dual tag affinity purification procedure.Whole cell
lysates from 293T cells transfected with either pADAR1-p150-V5 or pV5
empty vector and the proviral NL4-3 genome were subjected to immuno-
precipitation (IP) with the NiNTA Magnetic Beads followed by several
washes and elution of His-tagged native protein complex from the beads.
The eluted protein complex was then subjected to a second step of IP us-
ing the anti-V5-tag magnetic beads followed by several washes with NP40
buffer. The resulting beadswere resuspended in SDS loading buffer and the
proteins were separated by SDS-PAGE, visualized by Sypro–Ruby staining
and subjected to LC-MS/MS. The single asterisk indicates the p150 iso-
form of ADAR1-V5, the double asterisk corresponds to the ADAR1-V5
protein of about 110 kDa produced by translation machinery from a sec-
ondmethionine at position 296, as previously reported (69). Both isoforms
migrate as doublets of bands possibly due to post-translation modification
as originally observed (18). All the 14 non-ribosomal proteins identified as
putative ADAR1-interacting factors are indicated.
whereas the other binding proteins identified are novel in-
teractors.
Validation of the mass spectrometry results by co-
immunoprecipitation assay
Strikingly, TOP1, PABPC1, NCL, hnRNP L and HSPA1A
proteins were previously reported as associated with the
L1 ORF1 and/or ORF2 proteins and their ribonucleopro-
teins (RNPs) (30–32).Moreover, NCL, hnRNPL, PABPC1
were also demonstrated to play a role in the regulation of
the L1 activity (43,44). These results suggest a functional
link between ADAR1 and the L1 retrotransposon that we
further investigated. First of all, to confirm the interac-
tion of ADAR1 with the identified L1 RNP-associated pro-
teins and overall to validate the mass spectrometry results,
these selected proteins and other two putative ADAR1-
interactors that are well-known RNA- and DNA-binding
proteins (PSF and NONO) were analyzed for their capac-
ity to specifically bind to ADAR1-V5. To this aim, we co-
transfected 293T cells as described above and total cell ex-
tract prepared and subjected to co-immunoprecipitation ex-
periments (Co-IP) using anti-V5 tag magnetic beads fol-
lowed by WB analysis.
As shown in Figure 2, the putative interactors were con-
firmed to Co-IP with ADAR1-V5 and interestingly their
association with ADAR1 was found to be mostly RNA-
dependent and disappeared or reduced dramatically after
RNase treatment (Figure 2, left panel). The only exceptions
areNONOandHSPA1A that interactedwithADAR1 in an
RNA-independent manner (Figure 2, left panel). Complete
degradation of total RNA from cell lysate after RNase-
treatment was confirmed (Figure 2, right panel). Notably,
all these associations occur also in the absence of HIV-1 ex-
pression since they can be recapitulated in total cell extracts
prepared from 293T cells transfected only with pADAR1-
p150-V5 vector (Supplementary Figure S1). Unfortunately,
due to the low immunoblotting and immunoprecipitation
efficiency of various TOP1 antibodies employed in this
study, we could not test the interaction between ADAR1-
V5 and TOP1.
Next, we assayed the ability of the ADAR1-binding fac-
tors to associate with endogenous ADAR1. To this aim,
we performed Co-IP experiments using total cell extract
of 293T cells and specific antibodies against the putative
ADAR1-interactors (NCL, hnRNP L, HSPA1A, PABPC1,
PSF and NONO) followed by WB analysis with anti-
ADAR1 antibody. As shown in Figure 3, the selected pro-
teins associate with the endogenous ADAR1.
Overall, the Co-IP data strongly support MS sequenc-
ing results and validate the use of tagged-ADAR1 construct
for discovering cellular proteins that potentially associate
with ADAR1. Furthermore, we identified novel ADAR1-
interacting factors, a good fraction of which is shared with
the L1 RNP complexes.
ADAR1 regulates retrotransposition in a cell culture assay
Next, we sought to investigate whether ADAR1 is involved
in the regulation of L1 life cycle. We used previously es-
tablished cell culture L1 retrotransposition assays (34–36)
to determine the effect of down-regulation of endogenous
ADAR1 expression on the activity of engineered L1 retro-
transposons. First, to knockdown ADAR1 expression, we
transiently transfected HeLa cells with the three different
short hairpin (shRNA) plasmids and 72 h post-transfection
total cell extract was prepared and analyzed by WB us-
ing specific antibodies (Figure 4A). HeLa cells transfected
with anti-ADAR1 shRNA plasmids showed a reduction of
ADAR1 protein level of at least 60–70% compared to the
level in cells transfected with suitable controls (a plasmid
expressing the scramble shRNA or the empty vector) (Fig-
ure 4A). A GFP expression cassette cloned in the backbone
of the shRNA plasmids was used to normalize transfection
efficiency.
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Table 1. ADAR1-RNPs proteins in HIV-1 expressing cells identified by nano-LC MS/MS. ProteinPilot Unused ProtScore (Conf) >1.30 (95.0%). All the
14 non-ribosomal proteins indentified as putative ADAR1-interacting factors are separated from the ribosomal proteins and URB1 protein considered as
contaminants of the affinity purification procedure
Accession numbera Gene namea Protein Name
P55265 ADAR1 (DSRAD) Double-stranded RNA-specific adenosine deaminase
P23246 PSF (SFPQ) Splicing factor, proline-and glutamine-rich
P78563 ADAR2 (ADARB1) Double-stranded RNA-specific editase 1
O43143 DHX15 Pre-mRNA splicing factor ATP-dependent RNA helicase DHX15
P19338 NCL Nucleolin
P11142 HSPA8 Heat shock cognate 71 kDa protein
P11387 TOP1 DNA topoisomerase I
P11940 PABPC1 Polyadenylate-binding protein 1
Q15233 NONO (p54 nrb) Non-POU domain containing octamer-binding protein
P08107 HSPA1A/1B Heat shock 70 kDa protein 1A/1B
P14866 HNRNPL Heterogeneous nuclear ribonucleoprotein L
P34931 HSPA1L Heat shock 70 kDa protein 1-like
P07437 TUBB Tubulin beta chain
Q9UN86 G3BP2 Ras-GTPase-activating protein-binding protein 2
P68371 TUBB4B Tubulin beta-4B chain
O60287 URB1 Nucleolar pre-ribosomal-associated protein 1
P05388 RPLP0 60S acidic ribosomal protein P0
P62906 RPL10A 60S ribosomal protein L10a
P61313 RPL15 60S ribosomal protein L15
P50914 RPL14 60S ribosomal protein L14
P18124 RPL7 60S ribosomal protein L7
P62241 RPS8 40S ribosomal protein S8
P26373 RPL13 60S ribosomal protein L13
aAccording to the UniProtKB/Swiss–Prot entry.
Figure 2. Validation of the results of the nano-LC MS/MS data by co-immunoprecipitation (Co-IP) analysis. Lysates of 293T cells co-transfected with
pADAR1-p150-V5 or pV5 empty vector and the proviral NL4-3 genome were subjected to IP with anti-V5-tag magnetic beads (IP V5) followed by
Western blot (WB) analysis with anti-V5, anti-NONO, anti-PSF, anti-hnRNP L and anti-NCL, anti-HSPA1A and anti-PABPC1 antibodies (left panel).
Total cell lysates were mock-treated or RNase (A+V1)-treated prior to IP. WB analysis of 20 #g of cell lysate inputs (input) is shown. Complete RNA
digestion after RNase-treatment of the cell extract (lysate) prior IP was confirmed by loading a fraction of the treated and untreated cell extract onto 1%
agarose/formaldehyde gel followed by electrophoresis and ethidium bromide staining (right panel). The 28S and 18S rRNA are indicated.
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Figure 3. Validation of the results of the nano-LCMS/MS data by reciprocal IP. Lysate of 293T cells was subjected to IP using either IgGs or anti-NONO
or anti-PSF or anti- hnRNP L or anti-NCL or anti-HSPA1A or anti-PABPC1 antibodies followed by WB analysis using specific antibodies. WB analysis
of 20 #g of cell lysate inputs (input) is shown.
To test the effect of silencing of ADAR1 on L1 retro-
transposition, we employed a dual-luciferase retrotranspo-
sition assay using the pYX014 plasmid (36). This plasmid
is a retrotransposition cassette containing an engineered
L1 element harboring the Firefly luciferase (Fluc) gene as
retrotransposition indicator (36, Figure 4B). The Fluc re-
porter gene was cloned in the antisense orientation (rela-
tive to L1) in the 3′-untranslated region (3′-UTR) of L1 se-
quence and its coding sequence disrupted by an intron in
the sense orientation. Therefore, Fluc expression occurs in
the transfected cells only after one round of retrotranspo-
sition, in particular when the L1 is transcribed, the intron
is removed by splicing and the reverse transcription and the
integration is followed by transcription of the intact Fluc
gene. The resulting Firefly luciferase measurement serves as
read-out of L1 retrotransposition efficiency. A Renilla Lu-
ciferase expression cassette cloned in the backbone of the
pYX014 plasmid was used to normalize transfection effi-
ciency (36, Figure 4B). We transfected HeLa cells in tripli-
cate with anti-ADAR1 shRNA plasmids, and 48 h later we
further transfected them with the pYX014 plasmid. Four
days after pYX014 transfection, we lysed cells for lumines-
cence analysis and L1 activity measured as the Fluc/Rluc
ratio. As shown in Figure 4C knockdown of ADAR1 ex-
pression in HeLa cells increased L1 activity by 2- to 3-fold
when compared to controls (scramble shRNA and empty
vector). To confirm that Fluc signal was originated from
L1 retrotransposition, we performed experiments using the
pYX015 vector (36), instead of the pYX014, carrying a
missense mutation in the ORF1 coding sequence that dra-
matically impairs L1 retrotransposition. Using this vector
in ADAR1-silenced HeLa cells, following the same experi-
mental procedure described above, we measured only back-
ground levels of Fluc (data not shown). Therefore, these re-
sults suggest that ADAR1 is a regulator of L1 retrotrans-
position activity.
To further validate these results, we employed a differ-
ent and widely used pJM101/L1.3 retrotransposition cas-
sette (33,34). This cassette is similar to pYX014 described
above (Figure 4B), but the retrotransposition indicator Fluc
gene is substituted by the neomycin phosphotransferase
gene (mneoI). We measured retrotransposition efficiency by
counting the numbers of G418-resistant cells as a result of
new L1 insertions as previously described (33,34). In par-
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Figure 4. ADAR1 regulates L1 retrotransposition. (A) HeLa cells were transiently transfected with specific anti-ADAR1 shRNA plasmids or controls
(empty vector or scramble shRNA plasmid). WB analysis using anti-ADAR1 and anti-GAPDH antibodies of total cell extract prepared from the trans-
fected cells confirms the specific knock-down of ADAR1 protein 72 h after transfection. (B) Schematic representation of the pYX014 cassette and the
rational of L1 retrotransposition assay, as previously described (36). The Fluc indicator cassette is cloned into the L1 3′UTR in antisense orientation
relative to L1 transcription. This cassette has its own promoter (P2) and the Fluc coding sequence is interrupted by a gamma globin intron. An Rluc
cassette, containing its own promoter (P3), is incorporated into the backbone of the plasmid and allows measurement of the transfection efficiency. The
Fluc gene can by expressed only when the L1 transcript (L1 pre-mRNA) is spliced (L1 mRNA), reverse transcribed and inserted into genomic DNA. (C)
Representative Fluc retrotransposition assay results: HeLa cells previously transfected with anti-ADAR1 shRNA plasmids or control plasmids (empty
vector or scramble shRNA plasmid) were then transfected with the luciferase assay vector pYX014. Four days after pYX014 transfection and puromycin
selection, cells were lysed for luminescence analysis. The X-axis indicates the construct name. The Y-axis indicates the L1 activity measured as the ratio of
the Fluc/Rluc values as previously reported (36). Data are reported as the mean± SD from three independent experiments. Asterisks indicate statistically
significant differences from the scr shRNA sample (P-values were calculated by two-tailed t-test and are indicated above each histogram, *P < 0.05). (D)
Representative G418 retrotransposition assay results: HeLa cells previously transfected with anti-ADAR1 shRNA plasmids or control plasmids (empty
vector or scramble shRNA plasmid) were further transfected with the pJM101/L1.3 cassette. Seventy-two hours later, cells were grown in media supple-
mented with G418 and after ∼ 10 days of G418 selection, the remaining cells were fixed and then stained with crystal violet to facilitate the visualization
and allow the counting of the colonies formed for individual retrotransposition events. The X-axis in the graph indicates the constructs name. The Y-axis
indicates the number of G418-resistant foci per cell culture dish. Data are reported as the mean ± SD from three technical replicates of a single represen-
tative experiment. Asterisks indicate statistically significant differences from the scr shRNA sample (P-values were calculated by two-tailed t-test and are
indicated above each histogram, *P < 0.05). The experiment was conducted five times (biological replicates) with similar results. (E) Representative T25
flasks with crystal violet-stained G418-resitant HeLa colonies of the experiments described in (D) are shown. (F) Representative T25 flasks with crystal
violet-stained G418-resitant HeLa colonies of experiments performed as described in (D) by substituting the pJM101/L1.3 cassette with the pcDNA3.1
plasmid are shown.
ticular, using an experimental protocol similar to that de-
scribed above we transfected HeLa cells in triplicate first
with the anti-ADAR1 shRNA plasmids or control plas-
mids (empty vector and scramble shRNA vector), and 72
h post-transfection, we further transfected them with the
pJM101/L1.3 cassette. Forty eight hours later, cells were
grown in media supplemented with G418 and after ∼ 10
days of G418 selection, the remaining cells were fixed and
then stained with crystal violet to facilitate the visualiza-
tion and allow the counting of the colonies formed for indi-
vidual retrotransposition events. As shown in Figure 4D, E
and Supplementary Figure S2, knockdown of ADAR1 ex-
pression in HeLa cells increased L1 retrotransposition ef-
ficiency by at least 6-fold when compared to the controls
(scramble shRNA and empty vector) in five independent
transfection experiments. In order to confirm that the re-
sults obtained are due to the reduction of ADAR1 expres-
sion acting specifically on L1 retrotransposition, and not
to either a general or toxic effect of ADAR1 knockdown,
we carried out the same experiments described above using
the pcDNA3.1 vector instead of the pJM101/L1.3 cassette.
The pcDNA3.1 is a plasmid that confers to the transfected
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cells resistance to G418 without the need of retrotransposi-
tion. TheG418-resistant colonies were counted in theHeLa
cells silenced or not for ADAR1 expression after ∼ 10 days
of G418 selection and their numbers were equivalent (Fig-
ure 4F and data not shown). Moreover, we performed also
experiments using the pJM105/L1.3 cassette that is iden-
tical to pJM101/L1.3 but contains a missense mutation in
the RT domain of the ORF2 gene that dramatically reduces
L1 retrotransposition efficiency. Using the pJM105/L1.3
cassette in ADAR1 silenced HeLa cells we selected no or
just few G418-resistant colonies (data not shown). Overall,
these results demonstrate that the knockdown of the en-
dogenous ADAR1 expression in HeLa cells causes an in-
crease in L1 retrotransposition efficiency thus unveiling a
novel role forADAR1 as regulator of L1 retrotransposition.
The retrotransposition assays employed in this study are
based on the removal of the gamma globin intron for the ex-
pression of the reporter gene (Fluc or mneoI)) allowing the
measurement of the retrotransposition efficiency (Figure
4B). Since native L1 lacks introns, this raises the possibility
that alteration of endogenous ADAR1 protein level by us-
ing specific shRNAs may not affect directly the L1 life cycle
butmerely alters the efficiency in the removal of the artificial
intron contained within the cassettes. To exclude this pos-
sibility, we employed a previously described strategy based
onRT-qPCRexperiments (SupplementaryFigure S3, 44) to
measure the splicing efficiency of the globin intron harbored
within the pJM101/L1.3 cassette in HeLa cells previously
knocked-down for ADAR1 expression. As shown in Sup-
plementary Figure S3, silencing of ADAR1 expression does
not affect significantly the splicing efficiency when com-
pared to specific controls (HeLa cells transfected with scr
shRNA and empty vector), thus indicating that this mech-
anism cannot account for the increased L1 retrotransposi-
tion activity observed (Figure 4C and D) and confirming a
specific role of ADAR1 in the L1 life cycle.
To further confirm the suppression of LINE-1 retro-
transposition by ADAR1, it was evaluated whether over-
expression of this enzyme causes an impairment of L1 retro-
transposition.
Unfortunately, the ectopic expression of ADAR1 may
lead to erroneous result interpretation.
In fact, it has been previously demonstrated that co-
expression of ADAR1 increases any exogenous plasmid-
based gene expression independently of the type of the pro-
moter or reporter present in the plasmid (45). This effect is
caused by the reduction of the PKR (protein kinase regu-
lated by RNA) activation and phoshorylation of the PKR-
substrate eIF-2" mediated by the ectopic ADAR1 expres-
sion. This, in turn, leads to an increase of the exogenous
gene expression at the protein level up to 20- to 50-fold (45).
In the attempt of overcoming this problem, we assayed
the amount of the pADAR1-p150-V5 plasmid that trans-
fected in HeLa cells is sufficient to show an effect on L1
retrotransposition efficiency without affecting the eIF-2"
phosphorylation at Ser51 (normalized quantification of the
level of phospho-eIF-2" relative to the level of total eIF-
2").
To this aim, we transiently transfected HeLa cells with
a constant amount of the pYX014 retrotransposition cas-
sette and a decreasing amount of pADAR1-p150-V5 plas-
mid ranging from a 1:1 to 25:1 ratio. Four days after
transfection, we lysed transfected cells for both lumines-
cence analysis to measure L1 activity as the Fluc/Rluc ra-
tio and for WB analysis. As shown in Figure 5A, over-
expression ofADAR1-V5 (bottompanel) at all the amounts
of pADAR1-p150-V5 plasmid transfected caused a reduc-
tion of L1 retrotransposition efficiency compared to control
(cells transfected with pV5 empty vector) (Figure 5A, top
panel).
We repeated the transfection experiment described above
using a 5:1 ratio of the two plasmids and by luminescence
analysis confirmed the inhibition of L1 retrotrotrasposi-
tion mediated by the ADAR1 over-expression and by WB
analysis we demonstrated that no alteration of the level of
phosphorylation of eIF-2" protein occurred compared to
its level in control cells (cells transfected with pV5, Figure
5B middle panel).
Therefore over-expression of ADAR1, as expected,
causes inhibition of L1 retrotransposition.
ADAR1 deaminase domain is not required to restrict LINE-1
retrotransposition
We examined whether the RNA editing activity of ADAR1
was required for suppression of retrotransposition. To this
aim, we employed the pADAR1-Dcat plasmid that allows
the expression of an ADAR1 mutant deleted in the cat-
alytic deaminase function (Figure 5B, bottom panel). As
shown inFigure 5B (top panel), whenHeLa cells were trans-
fected with pADAR1-p150-V5 or pADAR1-Dcat plasmids
together with the pYX014 cassette (1:5 ratio to avoid effects
on eIF-2" phoshorylation level, Figure 5B middle panel)
we observed a reduction of L1 retrotransposition efficiency
compared to the control (cells transfected with pV5 plas-
mid). Only a slight difference, not statistically significant, in
reducing L1 retrotransposition was measured between cells
expressing ADAR1-V5 and ADAR1-Dcat mutant (Figure
5B, top panel) suggesting that the deaminase domain of
ADAR1 is either dispensable or plays a minor role in in-
hibiting retrotransposition.
ADAR1 binds the L1 RNP complex
To get further insight into the mechanism used by ADAR1
to inhibit L1 retrotransposition, we investigated whether
ADAR1 associates with the basal L1 RNP complex, as pre-
viously demonstrated for its putative binding-factors iden-
tified in this study, and hence possibly interferes with its ac-
tivity.
To this aim, we immunoprecipitated with anti-V5 anti-
body total cell lysate prepared from 293T cells previously
co-transfected with pADAR1-V5 or pV5 together with the
pES2TE1 plasmid. The pES2TE1 is an expression vector
of L1.3 retrotransposon containing an ORF1 fused to a
T7-Tag at the C terminus (35). We analyzed half of the
resulting immunocomplex by WB with antibodies specific
for the V5 and T7 tags showing that ADAR1-V5 does co-
immunoprecipitate the ORF1 protein (Figure 6A), even
though this association seems to be weak. From the re-
maining immunocomplex, we isolated total RNA that was
subjected to RT-PCR analysis with specific primers for the
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Figure 5. Inhibition of LINE-1 retrotransposition by ADAR1 over-expression. (A) Representative Fluc retrotransposition assay results: Hela cells were
co-transfected with a constant amount of the pYX014 retrotransposition cassette and a decreasing amount of pADAR1-p150-V5 plasmid ranging from
a 1:1 to 25:1 ratio. Four days post-transfection, cells were lysed for both luminescence analysis to measure L1 activity (top panel) and for WB analysis
(bottom panel) with anti-V5 and anti-GAPDH antibodies. In the top panel, the X-axis indicates the construct name and the plasmids ratio. The Y-axis
indicates the L1 activity measured as the ratio of the Fluc/Rluc values as previously reported (36). Data are reported as the mean ± SD from three
independent experiments. (B) HeLa cells were co-transfected with the pYX014 retrotransposition cassette together with a 5:1 ratio of either pADAR1-
p150-V5 plasmid or pADAR1-Dcat plasmid expressing a mutant of ADAR1 lacking the deaminase domain (bottom panel) or pV5 empty vector. Four
days post-transfection, cells were lysed for both luminescence analysis to measure L1 activity (top panel) and for WB analysis (middle panel) with anti-V5,
anti- eIF-2" and anti- P- eIF-2" antibodies. As positive control, HeLa cells were treated with 1 #M sodium arsenite for 48 h previously reported to induce
eIF-2" phoshorylation (middle panel). The ratio P- eIF-2" /total eIF-2" is indicated. In the top panel, the X-axis indicates the construct name. The Y-
axis indicates the L1 activity measured as the ratio of the Fluc/Rluc values as previously reported (36). Data are reported as the mean ± SD from four
independent experiments. Asterisks indicate statistically significant differences from the pV5 sample (P-values were calculated by two-tailed t-test and are
indicated above each histogram, **P < 0.005).
amplification of fragments of the ectopically expressed L1
RNA and endogenous actin mRNA, used as negative con-
trol. As shown in Figure 6B, ADAR1-V5 Co-IP the L1
RNA but not the actin mRNA. This result suggests that
ADAR1 may affect L1 retrotransposition by binding the
basal L1 RNP complex. Additional experiments showed
that ADAR1-V5 Co-IP also the endogenous L1 transcripts
(data not shown).
L1 RNA is not edited by ADAR1
Finally, we investigated whether ADAR1 binding to L1
RNA resulted in editing of retrotransposon sequences. To
this aim, total RNA isolated from 293T cells co-transfected
with pADAR1-V5 or pV5 together with the pcL1-FH retro-
transposition cassette was subjected to reverse transcription
and polymerase chain reaction (PCR) using specific primers
for the amplification of different fragments of the ectopi-
cally expressed L1 RNA followed by DNA Sanger sequenc-
ing. Inosine is interpreted as guanosine during reverse tran-
scription, therefore the A-to-I changes in the RNA appear
as A-to-G changes in the corresponding PCR products. By
using this experimental approach we did not identify any
editing event within the L1 sequence analyzed (more than
2.5 kb) (data not shown). This result is in agreement with
the experiments described above (Figure 5B), carried out
by using a plasmid expressing an ADAR1 mutant lacking
the catalytic domain (ADAR1-Dcat) and showing the neg-
ligible role of this domain in ADAR1 inhibition of L1 retro-
transposition.
This result supports a model in which ADAR1 affects L1
retrotransposition mainly by a mechanism that is editing-
independent.
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Figure 6. ADAR1 binds the basal L1 RNP complex without affecting the accumulation of its components. (A) Lysates of 293T cells transfected with either
pV5-ADAR1-p150 or pV5 empty vector together with pES2TE1 cassette were subjected to IP with anti-V5-tag magnetic beads (IP V5) followed by WB
analysis with anti-V5 and anti-T7 tag antibodies. WB analysis of 7 #g of cell lysate inputs (input) is shown. (B) Total RNA isolated from a fraction of
the immunocomplexes (IP V5) obtained in (A) and total RNA isolated from the co-transfected 293T cells with pV5-ADAR1-p150 plasmid together with
pES2TE1 cassette (input) were subjected to RT-PCR analysis using specific primers to amplify fragments of the ectopically expressed L1 RNA and actin
mRNA. (C) Results of the RT-qPCR experiments: HeLa cells previously transfected with anti-ADAR1 shRNAs or scr shRNA plasmids were further
transfected with the pES2TE1 cassette. Five days post-transfection the ectopically expressed L1 RNA level was determined. The X-axis indicates the
construct name. The Y-axis indicates the relative level of L1 RNA generated from the pES2TE1 cassette and normalized for the hygromycin mRNA level
generated from the same cassette. The ratio L1 RNA/HYG mRNA of the scr shRNA sample is assigned as 1. Data are reported as the mean ± SD from
three independent experiments. (D) ORF1p protein expression: total cell extract prepared from the HeLa cells transfected as described in (C) were analyzed
by WB using the anti-T7 and the anti-GAPDH antibodies. One WB analysis representative of three independent experiments is shown.
ADAR1 does not affect the accumulation of full length L1
RNA and ORF1p
Since ADAR1 binds the basal L1 RNP, we next asked
whether this interaction alters the activity of the complex
by affecting the accumulation of both the L1 RNA and the
translated ORF1p. To reach this goal, we transiently trans-
fectedHeLa cells previously knocked-down for ADAR1 ex-
pression with the pES2TE1 retrotransposition cassette fol-
lowed by hygromicyn selection. Five days post-transfection,
total RNA and total cell extract were prepared from the
transfected cells. Total RNA was subjected to an RT-qPCR
analysis to measure the level of L1 RNA by using specific
primers to amplify a fragment that span the ORF2/Flag-
HA sequence. These primers were designed to amplify ex-
clusively the exogenous L1RNAderived from the pES2TE1
cassette. Primers specific for the hygromycin phosphotrans-
ferase gene (HYG) present on the pES2TE1 plasmid were
used to amplify a fragment of the corresponding mRNA
that was used for normalization.
As shown in Figure 6C silencing of ADAR1 expression in
HeLa cells does not affect significantly the L1 RNA accu-
mulation.Moreover, theWB analysis of the total cell lysates
using specific antibodies anti-T7 tag and anti-GAPDH,
showed no significant alteration of the ORF1p protein in
cells silenced for ADAR1 expression compared to control
cells. Overall these results show that the knock-down of
ADAR1 expression in HeLa cells does not affect the accu-
mulation of the L1 RNA or ORF1p protein.
It is reasonable to envision that, even though ADAR1
binds the L1 RNP complex, suppression of the LINE-1 ac-
tivity occurs by a mechanism that does not cause an alter-
ation in the level of the L1 RNP components but impairs
some functions of the complex critical for the retrotranspo-
sition.
DISCUSSION
Herein we presented the first comprehensive study aimed at
identifying candidate ADAR1-interacting factors in HIV-1
expressing cells using a dual-tag affinity approach followed
by mass spectrometry analysis. Using this approach, we
identified 22 proteins. Excluding 7 ribosomal proteins and
the nucleolar pre-ribosomal-associated protein 1 (URB1)
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that are possibly contaminants of the affinity purification
procedure, the other 14 candidates include three heat shock
proteins, two components of the cytoskeleton and a large
number of proteins with a reported DNA and/or RNA
binding capacity. Some of these proteins are well known to
interact with HIV-1 components and/or affect viral repli-
cation thus suggesting that through their association with
ADAR1 may contribute to or modulate its proviral activ-
ity.
These proteins include Nucleolin that interacts with p55
Gag and it has been recently demonstrated to affect vi-
ral transcription (46,47). Moreover, Hsp70 proteins medi-
ate Tat activation and viral transcription, and are released
in HIV-1 virions (48–50). Both PSF and NONO bind the
HIV-1 RNA instability element (INS), but only PSF causes
a down-regulation of the Rev-dependent gag and env tran-
scripts (51).
Finally, the Ras GTPase-activating protein-binding pro-
tein 2 (G3BP2) is one of the main components of the cyto-
plasmic SGs (52,53) and G3BP proteins play a role in the
replication process of different viruses (54). Interestingly, it
has been recently reported that the HIV-1 Gag protein in-
hibits SG assembly (55).
Strikingly, 5 out of the 14 identified ADAR1-interacting
factors, such as TOP1, PABPC1, NCL, hnRNP L and
HSPA1A, were previously reported as associated with the
L1 ORF1p and/or ORF2p proteins and their ribonucleo-
proteins (30–32,43).
This unexpected result suggested a possible involvement
of ADAR1 in L1 life cycle and this hypothesis was further
investigated.
First, we assayed the interaction between ADAR1 and
these L1 RNP-associated proteins by Co-IP experiments.
Actually, we also tested additional proteins (NONO and
PSF) to validate the overall results of mass spectrometry
analysis. In particular, the tagged ADAR1-V5 was able to
Co-IP the selected endogenous ADAR1-interactors (hn-
RNPL,NONO, PSF, PABPC1,HSPA1AandNCL) and by
treatment with an RNase mix it was determined that most
of these associations are RNA-dependent. The only excep-
tions are the interactions between ADAR1 and the NONO
and HSPA1A proteins.
Moreover, the interactions we validated are maintained
also in the absence of HIV-1 expression, thus suggesting
that ADAR1 interacts with the L1 RNP-associated pro-
teins independently from viral replication. However, it is
reasonable to expect that some other interactors distinct
from those validated by Co-IP associate with ADAR1 only
during viral replication. Finally, by using specific antibodies
raised against PABPC1, HSPA1A, hnRNP L, NONO, PSF
and NCL the endogenous ADAR1 was Co-IP.
Of note, ADAR2 and NONO were previously described
to interact with ADAR1 (40–42), thus corroborating the re-
sults of our experimental approach.Nevertheless, other pre-
viously described ADAR1-binding factors were not identi-
fied in our study, such as PKR (6), PACT (19), NF90 pro-
teins (56), HuR (ELAVL1, 57), Tudor (58) and Dicer (59)
and others. The only plausible explanation for this discrep-
ancy is the different experimental settings used in these stud-
ies. In fact, prior to this study most of the ADAR1-binding
factors were identified by single IP experiments, instead of
two sequential IP experiments employed here, or by the use
of differently tagged-ADAR1 proteins/antibodies, different
cell lines and only another study employed the mass spec-
trometry analysis (60).
It is likely that our approach allowed the identification of
themost stable associations in 293T cells, as indicated by the
limited numbers of putative ADAR1-binding factors iden-
tified. In support of this hypothesis, in our validation Co-IP
experiments performedwith lysate prepared from293T cells
expressing the ADAR1-V5 protein, we were able to Co-IP,
using the anti-V5 antibody, the endogenous PKR protein
(not found in themass spectrometry analysis), also confirm-
ing that this interaction is strictly RNA-independent (data
not shown).
The interaction of ADAR1 with proteins shared with the
L1 RNP complexes suggests that this enzyme might play a
regulative role in L1 life cycle. This hypothesis is in agree-
ment with recent published results showing that cellular fac-
tors that restrict L1 retrotransposition are also involved in
the regulation of exogenous viruses (TREX1, APOBEC3
proteins, SAMHD1, MOV10, RNase L and ZAP) (32,61–
63), thus indicating a sort of selection during the evolution
of some host proteins to defend cells from endogenous and
exogenous parasites. To investigate whether ADAR1 affects
L1 activity, we employed two distinct and well-established
retrotransposition assay systems (33,34,36). By using these
assays, we demonstrated that silencing of ADAR1 expres-
sion in HeLa cells causes an increase in L1 retrotransposi-
tion. Conversely, ADAR1 over-expression inhibits L1 retro-
transposition.
An ADAR1 mutant lacking the deaminase domain
(ADAR1-Dcat) still acts as an L1 inhibitor at similar extent
compared to the wt protein, suggesting that RNA editing
plays a marginal role in this novel ADAR1 function.
This result is in agreement with the analysis of L1 RNA
sequence carried out by RT-PCR followed by DNA Sanger
sequencing that failed to detect any A-to-I change in the
retrotransposon sequence. The RT-PCR analysis was per-
formed using primer pairs designed to amplify specific frag-
ments of the ectopically expressed L1 RNA, with a signifi-
cant fraction of full length RNA competent for retrotrans-
position thus avoiding any contamination with the mixed
population of mostly truncated endogenous L1 RNAs.
Unfortunately, there are only few unique sequences in the
full-length ectopically expressed L1 RNA, thus this anal-
ysis was limited to almost half of the retrotransposon se-
quence. For this reason, we can’t exclude that A-to-I editing
might occur in the L1 regions we could not sequence.More-
over, it should be taken into account the possibility that a
small fraction of L1 RNA can be edited by ADAR1 or that
editing occurs at very low frequency below the threshold of
detection by using an RT-PCR approach. In any event, it
seems that if editing occurs within L1 RNA sequence this
modification might affect only marginally the retrotranspo-
sition efficiency.
The use of a deep sequencing approach to conduct an un-
biased genome-wide screening of A-to-I editing sites in the
transcriptome of human adult brain, revealed the presence
of editing sites within the LINE sequences (64). They are
generally located in truncated LINE-1 elements that reside
in 3′ UTR of transcripts in tandem repeats allowing the for-
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mation of extensive dsRNA structures that are good target
for ADAR1 binding and editing.
Hence, we can’t exclude that retrotransposition of en-
dogenous intragenic and full-length LINE-1 elements
might be restricted through RNA editing of their sequence.
In addition, we demonstrated that ADAR1 binds the
basal L1 RNP complex, in particular the L1 RNA (both
endogenous and ectopically expressed) and theORF1p pro-
tein. The interaction between ADAR1 and ORF1p protein
seems to be weak, requiring prolonged exposure of the WB
filters to detect it, indicating that probably this enzyme in-
teracts more stably with the LINE-1 RNA. In agreement
with this result, Bahn et al. (65) recently reported the first
global study of ADAR1–RNA interaction in human cells
using CLIP-seq and demonstrated an interaction between
endogenous ADAR1 and L1 RNA that was further con-
firmed by RNA immunoprecipitation (RIP)-PCR experi-
ments (65).
Notably, both L1 RNA and ORF1p protein were pre-
viously reported to localize in SGs (35,66). ADAR1 was
shown to localize within the same granules in HeLa cells
following several type of stress (58).Moreover, it was shown
that the Z"-DNA-binding domain of the p150 isoform is
required for this specific localization (67). Thus, it is con-
ceivable that ADAR1 p150 may interact with the L1 RNP
complex within SG. To further strength this hypothesis, in
this study we report the interaction between ADAR1 and
twomain components of the SG,G3BP2 and PABPC1 (53).
Interestingly, it has been recently reported that SAMHD1
inhibits L1 retrotransposition by promoting SG formation
and sequestration of the retrotransposon complex in these
granules, thus interfering with the nuclear import of LINE-
1 RNA and its subsequent reverse transcription and inte-
gration into genomic DNA (68).
Further experiments are required to investigate whether
ADAR1 and other retrotransposon restriction factors may
inhibit L1 activity using the same mechanism.
To investigate how ADAR1 inhibits LINE-1 activity, we
analyzed whether the interaction of ADAR1 with the L1
RNP complex may cause a reduction in the accumulation
of the L1 RNA and ORF1p protein. This analysis showed
that the knockdown of ADAR1 expression in HeLa cells
does not cause a significant alteration in the accumulation
of the L1 RNP components.
Hence, the more plausible explanation for the inhibitory
effect of ADAR1 on L1 retrotransposition is that the bind-
ing of the enzyme to the basal L1 RNP complex might in-
terfere with its activity without affecting the accumulation
of its components.
Further experiments are required to determine this in-
hibitory activity of ADAR1 thus paving the way toward a
better comprehension of the cell defense against exogenous
and endogenous parasites.
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